Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: A report of the Canadian Blood and Marrow Transplant Group

Journal of Clinical Oncology

Volumn 31, Issue 9, 2013, Pages 1164-1171

  Villa, Diego ^a,g   Crump, Michael ^a   Panzarella, Tony ^a,b   Savage, Kerry J ^g   Toze, Cynthia L ^h   Stewart, Douglas A ⁱ   MacDonald, David A ^k   Buckstein, Rena ^c   Lee, Christina ^c   Alzahrani, Mohsen ^k   Rubinger, Morel ^l   Foley, Ronan ^d   Xenocostas, Anargyros ^e   Sabloff, Mitchell ^f   Muccilli, Alexandra ^f   Chua, Neil ^j   Couture, Felix ^m   Larouche, Jean François ^m   Cohen, Sandra ⁿ   Connors, Joseph M ^g   Ambler, Kimberley ^g   Al Tourah, Abdulwahab ^g   Ramadan, Khaled M ^h   Kuruvilla, John ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

ⁱ TOM BAKER CANCER CENTRE   (Canada)

^j CROSS CANCER INSTITUTE   (Canada)

^k QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^l CANCERCARE MANITOBA   (Canada)

^m LAVAL UNIVERSITY   (Canada)

ⁿ MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANADA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSFORMED FOLLICULAR LYMPHOMA; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84875987846     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.0693     Document Type: Article

References (37)

1. Al-Tourah AJ, Gill KK, Chhanabhai M, et al: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 26:5165-5169, 2008
2. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997 (Pubitemid 27167397)
3. Montoto S, Davies AJ, Matthews J, et al: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426-2433, 2007 (Pubitemid 47007616)
4. Giné E, Montoto S, Bosch F, et al: The follicular lymphoma international prognostic index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539-1545, 2006 (Pubitemid 44542041)
5. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993 (suppl 5) (Pubitemid 23319044)
6. Yuen AR, Kamel OW, Halpern J, et al: Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726-1733, 1995
7. Eide MB, Lauritzsen GF, Kvalheim G, et al: High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas: A Norwegian multi centre phase II study. Br J Haematol 152:600-610, 2011
8. Williams CD, Harrison CN, Lister TA, et al: High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19:727-735, 2001 (Pubitemid 32119087)
9. Chen CI, Crump M, Tsang R, et al: Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 113:202-208, 2001 (Pubitemid 32423324)
10. Ramadan KM, Connors JM, Al-Tourah A, et al: Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma. Blood 112:4459, 2008 (abstr)
11. Friedberg JW, Neuberg D, Gribben JG, et al: Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 5:262-268, 1999
12. Foran JM, Apostolidis J, Papamichael D, et al: High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre. Ann Oncol 9:865-869, 1998 (Pubitemid 28440445)
13. Sabloff M, Atkins HL, Bence-Bruckler I, et al: A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 13: 956-964, 2007 (Pubitemid 47055389)
14. Andreadis C, Schuster SJ, Chong EA, et al: Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant 36:955-961, 2005 (Pubitemid 41741558)
15. Ban-Hoefen M, Kelly JL, Bernstein SH, et al: High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 53:830-835, 2012
16. Ramadan KM, Connors JM, Al-Tourah AJ, et al: Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: Long-term results. Bone Marrow Transplant 42:601-608, 2008
17. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
18. Rezvani AR, Storer B, Maris M, et al: Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26:211-217, 2008
19. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
20. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
21. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group hematology and oncology study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
22. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
23. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
24. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase II randomized intergroup study. J Clin Oncol 28:2853-2858, 2010
25. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
26. Feugier P, Van Hoof A, Sebban C, et al Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
27. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
28. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
29. Pfreundschuh M, Schubert J, Ziepert M, et al Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
30. Bains P, Al Tourah A, Campbell BA, et al Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol [epub ahead of print on October 3, 2012]
31. Al-Tourah AJ, Savage KJ, Gill KK, et al: Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood 110, 2007 (abstr 790)
32. Ramadan KM, Connors JM, Gascoyne RD, et al: Prior rituximab reduces relapse and improves survival following high dose chemotherapy and stem cell transplantation for relapsed composite low and intermediate grade (including transformed) lymphoma. Blood 108, 2006 (abstr 3662)
33. Tan D, Rosenberg SA, Lavori P, et al: Improved prognosis after histologic transformation (HT) of follicular lymphoma: The Stanford experience 1960-2003. Ann Oncol 19:iv111, 2008 (suppl 4; abstr 089)
34. Canadian Blood and Marrow Transplant Group. http://www.cbmtg.org/
35. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-sponsored International Working Group. J Clin Oncol 17:1244, 1999
36. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Logan BR, Zhang MJ, Klein JP: Regression models for hazard rates versus cumulative incidence probabilities in hematopoietic cell transplantation data. Biol Blood Marrow Transplant 12:107-112, 2006 (suppl 1) (Pubitemid 43034129)